Literature DB >> 20872277

Combined activity of oridonin and wogonin in advanced-stage ovarian cancer cells: sensitivity of ovarian cancer cells to phyto-active chemicals.

Sophie Chen1, Matt Cooper, Matt Jones, Thumuluru Kavitha Madhuri, Julie Wade, Ashleigh Bachelor, Simon Butler-Manuel.   

Abstract

The initial response rates of advanced-stage epithelial ovarian cancer to the chemotherapeutic agents carboplatin and paclitaxel are high. However, once drug resistance develops, further chemotherapy is less effective. The objective of this study is to investigate the anti-proliferative activity of the phyto-active chemicals (PACs) oridonin and wogonin in chemo-resistant epithelial ovarian cancer cells. Primary cell cultures from the ascitic fluid of three patients at diagnosis, two patients chemo-resistant to carboplatin and paclitaxel, and one patient treated with letrozole for breast cancer were studied and compared to the ovarian cancer cell lines A2780 and PTX10, by cell viability assay (MTS). Effects on cell cycle modulation and apoptosis were examined by flow cytometry and Western blot analysis (WB). WB was further conducted to investigate protein expressions altered by PACs. The results show that IC(50) of the primary cultures ranged from 0.6 to 5.4 μg/ml for oridonin and 0.3-12.7 μg/ml for wogonin. The paclitaxel-resistant cell line PTX10 was more sensitive to each of the PACs than the chemo-sensitive cell line A2780. Of particular interest is that in combination, the two PACs were synergistic in their cytotoxicity to five of six of the primary cultures and to both the cell lines (combination indices of 0.39-0.95). The inhibition is attributable to apoptosis and cell cycle modulation induced by the PACs as demonstrated in A2780 and PTX10. Up-regulation of the functional p53 protein in A2780 and down-regulation of Akt protein in PTX10 have in part contributed to the apoptosis. These findings suggest that oridonin and wogonin may have activity in ovarian cancer following its development of resistance to carboplatin and paclitaxel.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20872277     DOI: 10.1007/s10565-010-9176-0

Source DB:  PubMed          Journal:  Cell Biol Toxicol        ISSN: 0742-2091            Impact factor:   6.691


  8 in total

1.  BRCA1 185delAG Mutation Enhances Interleukin-1β Expression in Ovarian Surface Epithelial Cells.

Authors:  Kamisha T Woolery; Mai Mohamed; Rebecca J Linger; Kimberly P Dobrinski; Jesse Roman; Patricia A Kruk
Journal:  Biomed Res Int       Date:  2015-08-19       Impact factor: 3.411

Review 2.  Molecular Insight in the Multifunctional Effects of Oridonin.

Authors:  Brice Ayissi Owona; Herman J Schluesener
Journal:  Drugs R D       Date:  2015-09

Review 3.  Chinese medicines induce cell death: the molecular and cellular mechanisms for cancer therapy.

Authors:  Xuanbin Wang; Yibin Feng; Ning Wang; Fan Cheung; Hor Yue Tan; Sen Zhong; Charlie Li; Seiichi Kobayashi
Journal:  Biomed Res Int       Date:  2014-10-14       Impact factor: 3.411

Review 4.  Advances of wogonin, an extract from Scutellaria baicalensis, for the treatment of multiple tumors.

Authors:  Xue Wu; Haijun Zhang; Jumah Masoud Mohammad Salmani; Rong Fu; Baoan Chen
Journal:  Onco Targets Ther       Date:  2016-05-17       Impact factor: 4.147

5.  Therapy Effects of Wogonin on Ovarian Cancer Cells.

Authors:  Jiang Ruibin; Jin Bo; Wan Danying; Zhu Chihong; Feng Jianguo; Gu Linhui
Journal:  Biomed Res Int       Date:  2017-10-18       Impact factor: 3.411

6.  Wogonin Increases Cisplatin Sensitivity in Ovarian Cancer Cells Through Inhibition of the Phosphatidylinositol 3-Kinase (PI3K)/Akt Pathway.

Authors:  Feng Xing; Cong Sun; Ning Luo; Yuanying He; Mengmeng Chen; Siyu Ding; Chenghua Liu; Lijin Feng; Zhongping Cheng
Journal:  Med Sci Monit       Date:  2019-08-12

Review 7.  Oridonin and its derivatives for cancer treatment and overcoming therapeutic resistance.

Authors:  Xi Liu; Jimin Xu; Jia Zhou; Qiang Shen
Journal:  Genes Dis       Date:  2020-07-05

8.  Selection for high oridonin yield in the Chinese medicinal plant Isodon (Lamiaceae) using a combined phylogenetics and population genetics approach.

Authors:  Eric S J Harris; Shugeng Cao; Sean D Schoville; Chengming Dong; Wenquan Wang; Zaiyou Jian; Zhongzhen Zhao; David M Eisenberg; Jon Clardy
Journal:  PLoS One       Date:  2012-11-27       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.